- RecruitingPHASE2, PHASE3
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
This study looks at new treatments for endometrial cancer based on specific cancer features. It aims to find better ways to treat patients after surgery, potentially leading to personalised care for different types of endometrial cancer.
For: Endometrial CancerCanada · France · Netherlands - RecruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
For: LeukemiaUnited States · Australia · Austria - Active not recruitingPHASE2
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
This study compares two treatments for stomach or food pipe cancer that has a high chance of coming back after surgery. It's looking at whether a new immunotherapy combination works better than standard chemotherapy to prevent the cancer from returning.
For: Gastric and Esophagogastric Junction AdenocarcinomaCzechia · France · Germany - RecruitingPHASE2, PHASE3
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
This study aims to improve treatment and understanding of childhood ependymoma. It involves different treatment approaches, including chemotherapy and radiotherapy, for children and young adults up to 22 years old. The goal is to find better ways to help these patients.
For: Childhood EpendymomaAustria · Belgium · Czechia - Active not recruitingPHASE3
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors
This study looks at a special type of radiation (SABR) for people with cancer that has spread a little (4-10 spots). It compares SABR to usual treatments to see if it helps people live longer, keeps cancer away, and improves their quality of life.
For: Metastatic TumorsAustralia · Canada · Netherlands - RecruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
For: Non-small Cell Lung CancerUnited States · Argentina · Belgium - Active not recruitingPHASE3
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
This study looks at a new drug, bemarituzumab, in combination with standard chemotherapy and nivolumab for advanced stomach or food pipe cancer. It aims to see if this new combination is safe and works better than current treatments, helping people with specific types of cancer live longer.
For: Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This study looks at new drug combinations for stomach or food pipe cancer that has spread. It compares an experimental treatment with standard care, aiming to find better ways to treat patients whose cancer has specific features.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Argentina · Australia